PTHL - Pheton Holdings Total Debt to Capital

Public company logo of Pheton Holdings Limited (PTHL)

The market trend for Pheton Holdings Ltd (PTHL) shares demonstrates a dependence on the implementation of tumor irradiation software in China, with the individual debt-to-equity ratio standing at 0.03. The business relies on the supply of radiological systems and the service support of consumables. Growth is constrained by medical testing costs, stringent regulatory oversight, and specific lobbying within the Chinese region.

PTHL: Pheton Total Debt to Capital 09/06/2024 - 01/16/2026
Core merchandise of Pheton Holdings

Investors are assessing the resilience of Pheton Holdings Ltd (PTHL) through the total liabilities-to-equity ratio, which determines the business's degree of dependence on debt financing. When analyzing changes in the debt-to-equity ratio, it is critical to understand how high software development costs and regulatory risks in China impact the debt load, balancing financial security against the efficiency of return on investment.

Competitor analysis for Pheton Holdings Ltd

Debt to Equity Haleon|Kenvue Inc - Aggregate Debt to Equity|Total Debt to Capital VRNA|MENS (Jyong Bio) - All Debt to Shareholders' Equity Ratio|Total Debt to Capital LGND (Ligand Pharmaceuticals)|Total Debt to Capital amneal.com AMRX|PRGO - Debt to Equity|All Debt to Shareholders' Equity Ratio ALVO (Alvotech S.A.)|Liquidia Technologies (LQDA) - Debt to Equity|Total Debt to Equity Ratio Galapagos Corp|ANIP (ANI Pharmaceuticals) - Total Debt to Capital|Total Debt to Capital mannkindcorp.com|Total Debt to Equity Ratio AMPH (Amphastar Pharmaceuticals, Inc.)|PCRX (Pacira Pharmaceuticals) - All Debt to Shareholders' Equity Ratio|Debt to Equity ARS Pharma SPRY|Theravance Corp (TBPH) - Debt to Capital|AQST: Total Debt to Equity Ratio|scPharmaceuticals Inc. - Aggregate Debt to Capital|TECX: Total Debt to Capital|Tonix Pharma - All Debt to Shareholders' Equity Ratio|SXTC (SXT Pharmaceuticals) - Total Debt to Capital|Debt to Capital Eupraxia Pharma EPRX|Debt to Equity BioHarvest Sciences (BHST)|EXOZ (invizyne.com) - All Debt to Shareholders' Equity Ratio|Debt to Equity Oramed Pharmaceuticals Inc. ORMP|ENTX (Entera Bio Ltd) - Aggregate Debt to Equity|MindWalk - Total Debt to Capital|All Debt to Shareholders' Equity Ratio ABVC (ABVC BioPharma, Inc)|CPIX: Total Debt to Capital|Debt to Capital quantumbiopharma.com (QNTM)|Total Debt to Equity Ratio FGEN|TELO (Telomir Pharmaceuticals Inc) - Aggregate Debt to Capital|Debt to Equity Rani Therapeutics (RANI)|SNYR - Debt to Capital|Debt to Equity Rallybio RLYB|LEXX: Debt to Equity Ratio|PULM: Total Debt to Equity Ratio|All Debt to Shareholders' Equity Ratio APM (Aptorum Group Limited)|LYRA: Total Debt to Capital|Impact BioMedical, Inc. - All Debt to Shareholders' Equity Ratio|Debt to Equity TNF Pharmaceuticals Inc.|Debt to Capital cbdMD Corp YCBD|Debt to Equity PainReform (PRFX)|Debt to Equity CYTO (altamiratherapeutics.com)|Total Debt to Capital LIPO (Lipella)|OPTN: Debt to Equity Ratio|Pieris Pharmaceuticals - Total Debt to Capital|Total Debt to Capital Coefficient procapsgroup.com PROC|Petros Pharmaceuticals, Inc. (PTPI) - Debt to Equity|Debt to Equity Ratio QLI|SLRN (ACELYRIN, Inc.) - Total Debt to Capital|TFFP - Debt to Capital Ratio